ValuEngine downgraded shares of Medidata Solutions (NASDAQ:MDSO) from a hold rating to a sell rating in a research note issued to investors on Saturday morning.
Several other equities analysts also recently weighed in on the stock. TheStreet upgraded shares of Medidata Solutions from a c+ rating to a b- rating in a research note on Monday, March 12th. Zacks Investment Research downgraded shares of Medidata Solutions from a buy rating to a hold rating in a research note on Thursday, February 15th. Needham & Company LLC reduced their target price on shares of Medidata Solutions to $75.00 and set a buy rating for the company in a research note on Friday, February 9th. Morgan Stanley reduced their target price on shares of Medidata Solutions from $86.00 to $79.00 and set an overweight rating for the company in a research note on Friday, February 9th. Finally, Royal Bank of Canada set a $82.00 target price on shares of Medidata Solutions and gave the stock a hold rating in a research note on Thursday, February 8th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have assigned a buy rating to the stock. Medidata Solutions currently has a consensus rating of Buy and a consensus price target of $82.07.
Medidata Solutions (NASDAQ:MDSO) opened at $66.87 on Friday. The firm has a market cap of $3,960.91, a PE ratio of 90.36, a PEG ratio of 3.52 and a beta of 1.56. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.49 and a quick ratio of 1.49. Medidata Solutions has a 12 month low of $54.91 and a 12 month high of $85.92.
Medidata Solutions (NASDAQ:MDSO) last posted its earnings results on Thursday, February 8th. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.10. The firm had revenue of $141.20 million during the quarter, compared to the consensus estimate of $140.65 million. Medidata Solutions had a net margin of 8.14% and a return on equity of 11.59%. The company’s revenue was up 13.4% on a year-over-year basis. During the same quarter last year, the company earned $0.33 earnings per share. equities research analysts expect that Medidata Solutions will post 0.93 EPS for the current fiscal year.
In related news, CFO Rouven Bergmann sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $65.95, for a total transaction of $131,900.00. Following the completion of the transaction, the chief financial officer now owns 89,775 shares of the company’s stock, valued at $5,920,661.25. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Tarek Sherif sold 26,836 shares of the business’s stock in a transaction that occurred on Monday, March 12th. The shares were sold at an average price of $70.25, for a total transaction of $1,885,229.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 35,836 shares of company stock valued at $2,494,989. 5.80% of the stock is owned by corporate insiders.
A number of large investors have recently modified their holdings of MDSO. Ark Investment Management LLC grew its stake in Medidata Solutions by 696.2% during the second quarter. Ark Investment Management LLC now owns 74,769 shares of the company’s stock valued at $5,847,000 after acquiring an additional 65,378 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Medidata Solutions by 570.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 66,589 shares of the company’s stock worth $5,208,000 after buying an additional 56,653 shares in the last quarter. Nationwide Fund Advisors grew its stake in Medidata Solutions by 5.5% in the 3rd quarter. Nationwide Fund Advisors now owns 779,542 shares of the company’s stock worth $60,851,000 after buying an additional 40,837 shares in the last quarter. First Trust Advisors LP grew its stake in Medidata Solutions by 25.2% in the 3rd quarter. First Trust Advisors LP now owns 44,389 shares of the company’s stock worth $3,465,000 after buying an additional 8,943 shares in the last quarter. Finally, Stevens Capital Management LP purchased a new position in Medidata Solutions in the 3rd quarter worth approximately $509,000. 97.52% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Medidata Solutions (MDSO) Downgraded to “Sell” at ValuEngine” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://ledgergazette.com/2018/03/18/medidata-solutions-mdso-downgraded-to-sell-at-valuengine.html.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.